Date: September 21, 2026

Ownership & Strategic Disclosures

Disclosing Entity: Essix Biosciences Limited (Acquirer), acting on behalf of itself and 19 Persons Acting in Concert (PACs) belonging to the Promoter and Promoter Group of Ind-Swift Laboratories Limited (Target Company).

Details of Acquisition:

  • Instrument Acquired: 70,00,000 (Seventy Lakh) Fully Convertible Warrants
  • Face Value: Rs. 10/- each
  • Mode of Acquisition: Preferential allotment by the Target Company
  • Date of Allotment: September 17, 2026
  • Consideration: For cash

Pre-Acquisition Holding (Promoter & Promoter Group):

  • Shares carrying voting rights: 3,73,34,278 shares (43.06% of total share/voting capital)
  • Essix Biosciences Limited: 3,28,82,521 shares (37.92%)
  • PACs: 44,51,757 shares (5.13%)
  • Encumbered Shares: 0 (0.00%)
  • Other voting rights: 0 (0.00%)
  • Warrants/Convertible Instruments: 0 (0.00%)
  • Total Holding (a+b+c+d): 43.06%

Details of Current Acquisition:

  • Warrants/Convertible Instruments Acquired: 70,00,000 warrants by Essix Biosciences Limited
  • This acquisition represents: 7.45% of the total diluted share/voting capital post-acquisition

Post-Acquisition Holding (Promoter & Promoter Group):

  • Shares carrying voting rights: 3,73,34,278 shares (42.93% of total share/voting capital)
  • Essix Biosciences Limited: 3,28,82,521 shares (37.81%*)
  • PACs: 44,51,757 shares (5.12%*)
  • Encumbered Shares: 0 (0.00%)
  • Other voting rights: 0 (0.00%)
  • Warrants/Convertible Instruments: 70,00,000 warrants held by Essix Biosciences Limited (7.45% of diluted capital)
  • Total Potential Holding (a+b+c+d): 47.18% of diluted share/voting capital

*Note: Percentages for shares carrying voting rights are calculated on the post-preferential share capital of 8,69,61,558 Equity Shares, which includes 2,50,000 Equity Shares allotted pursuant to the exercise of ESOPs.

Capital Structure Impact:

  • Equity share capital before acquisition: Rs. 86,71,15,580/- comprising 8,67,11,558 Equity Shares of Rs. 10/- each
  • Equity share capital after acquisition: Rs. 86,96,15,580/- comprising 8,69,61,558 Equity Shares of Rs. 10/- each
  • Total diluted share/voting capital after acquisition: Rs. 93,96,15,580/- comprising 9,39,61,558 Equity Shares of Rs. 10/- each

Persons Acting in Concert (PACs):

The disclosure is made by Essix Biosciences Limited on behalf of the following 19 PACs:

1. Gopal Munjal

2. Himanshu Jain

3. N.R. Munjal

4. Rishav Mehta

5. S.R. Mehta

6. V.R. Mehta

7. Annie Mehta

8. Bhanavi Mehta

9. Divya Munjal

10. Ishav Mehta

11. Meenakshi Mehta

12. Neeta Munjal

13. Nidhi Munjal

14. Ravi Mehta

15. Sahil Munjal

16. Sunita Jain

17. Saurabh Munjal

18. Deepti Munjal

19. Daksh Mehta

Regulatory Context: This disclosure is made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition was intimated to Ind-Swift Laboratories Limited on September 21, 2026, who subsequently forwarded it to the stock exchanges.